Key Takeaways
- CBD shows significant potential in reducing seizure frequency for children with drug-resistant epilepsy, with a responder rate of 41.3% in randomized trials and 49.8% in observational studies.
- The recent review highlights a gap in cognitive and behavioral data, with most studies focusing solely on seizure outcomes.
- Families should consult neurologists when considering CBD, as individual responses vary and past treatments may influence outcomes.
- Long-term assessments indicate better responder rates, suggesting children benefiting from CBD might continue in studies.
- Overall, while CBD’s efficacy is supported, further research is needed to address broader quality of life aspects and draw placebo-adjusted comparisons.
Drug-resistant epilepsy in children is tough to treat. Families dealing with conditions like Dravet syndrome or Lennox-Gastaut syndrome have spent years looking for options beyond standard anti-seizure medications. CBD has become one of the more talked-about additions to that toolkit. This is partly because of its established role through Epidiolex, the first and still currently the only FDA-approved prescription CBD for seizures tied to Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex.
The new review, authored by researcher Andrea D. Praticò and published in Epilepsy Research, set out to get a clearer picture of how often CBD actually helps. The paper is online now and slated for the December issue of the journal.
Researchers combed through PubMed/MEDLINE, following PRISMA 2020 guidelines, and landed on 63 eligible studies spanning 92 research reports. Most of that literature, 56 out of 63 studies (88.9%), came from observational research rather than randomized controlled trials.
CBD Seizure Reduction by Study Type
One of the more useful findings in this review is the split between randomized trials and observational studies. In the CBD arms of randomized trials, 41.3% of children reached that 50% seizure reduction threshold. In observational studies, the figure climbed to 49.8%.
That gap makes sense once you think about how each type of study works. Randomized trials assess every enrolled patient over a fixed window, with no cherry-picking involved. In contrast, observational studies often reflect real-world practice, where patients who aren’t responding may discontinue treatment or get excluded from later reporting. There’s also the matter of placebo response and natural fluctuation in seizure activity. Both of these tend to inflate numbers in uncontrolled settings.
Follow-up length told a similar story. Short-term assessments (three months or less) showed a 42.8% responder rate, while long-term assessments (past six months) showed 57.4%. The review’s authors were upfront that this doesn’t necessarily mean CBD gets more effective with time. Instead, it’s more likely that children who are benefiting stick around for long-term follow-up. Those who aren’t tend to drop out or switch treatments.
Comparing This Review to Earlier CBD Research
Cannabis news readers may remember an earlier piece we covered on Beard Bros Pharms, which looked at a 2024 systematic review in Acta Epileptologica covering six randomized controlled trials in Lennox-Gastaut and Dravet syndrome patients. That earlier review found CBD-treated patients had an average seizure reduction of 41.1%, compared to 18.1% in placebo groups.
At first glance, that 41.1% figure looks almost identical to the 41.3% responder rate for randomized trials in this new review. But these two numbers are measuring different things, and mixing them up would be a mistake.
The 41.1% from our earlier coverage is an average percent reduction in seizure frequency across a treatment group. It’s a continuous measure that captures the full range of outcomes, from modest improvement to dramatic reduction, averaged across all patients.
The 41.3% from the new Epilepsy Research review is a responder rate. It’s the share of children who crossed a specific threshold, at least a 50% drop in seizures, regardless of how much further beyond that threshold they went. A child who went seizure-free counts the same as a child who dropped from 40 seizures a month to 19.
So while both numbers land in a similar range and both point toward CBD having a real effect, they’re not directly comparable statistics. One measures degree of improvement on average; the other measures how many people cleared a specific bar.
What a 50% Seizure Reduction Means (and Why It’s Not a Placebo-Adjusted Number)
When researchers talk about a “responder,” they mean a patient whose seizure frequency dropped by at least half compared to baseline. For example, if a child was having 40 seizures a month before treatment and is now having 20 or fewer, that child counts as a responder in this framework. It’s a threshold, not a guarantee of seizure freedom, and it says nothing about how much further improvement (or lack of it) occurred beyond that point.
Here’s the part that matters for interpreting these numbers correctly: a responder rate on its own is not a placebo-adjusted treatment effect. The 48.4% pooled rate from this review, and the 41.3% rate specific to randomized trial CBD arms, both reflect how many children improved while taking CBD. However, neither number subtracts out how many children would have reached that same 50% threshold without CBD, whether from placebo response, natural seizure variability, or regression to the mean.
Getting a true placebo-adjusted effect requires a randomized, controlled comparison. This is usually calculated as a risk difference or relative risk between treatment and placebo arms. Observational studies, which made up the bulk of this review, don’t have a placebo arm at all. As a result, there’s no way to extract that adjusted figure from them.
The Cognitive and Behavioral Data Gap
Seizure control tends to dominate CBD research, and this review is a clear example of that pattern. Seizure outcomes were reported in 98.4% of the 63 included studies. Cognitive outcomes, by contrast, showed up in only 7.9% of studies, and behavioral outcomes appeared in just 27%.
For families managing conditions like Dravet syndrome or Lennox-Gastaut syndrome, thats important. These are developmental and epileptic encephalopathies, meaning the impact goes well beyond seizure counts. Furthermore, cognitive development, behavior, sleep quality, and overall functioning are all part of the picture that parents and clinicians care about. Yet the research base barely touches most of that.
The review’s authors called for future pediatric CBD studies to build in standardized, longitudinal measures of cognition and behavior alongside seizure tracking. Until that happens, the field will keep producing strong data on seizure frequency while leaving bigger questions about overall quality of life only partially answered.
Where This Leaves Families and Clinicians
This review adds weight to what a lot of people in the cannabis and epilepsy space already suspected. CBD has a real, measurable effect on seizure frequency for a meaningful share of children with drug-resistant epilepsy. That effect holds up whether you’re looking at randomized trials or real-world observational data. Epidiolex’s FDA approval for specific syndromes reflects that established clinical role.
At the same time, the numbers come with context that shouldn’t get lost in a headline. Responder rates aren’t the same as seizure freedom. Observational data tends to run a bit higher than randomized trial data. The field still has real gaps in tracking cognitive and behavioral outcomes. Therefore, families considering CBD as part of a treatment plan should work closely with a neurologist to weigh these findings against their child’s specific situation. This is important since drug-resistant epilepsy varies widely from one case to the next.
Frequently Asked Questions
Not quite. The higher responder rates in observational studies (49.8% vs. 41.3% in randomized trials) and in long-term follow-up (57.4% vs. 42.8% in short-term assessments) most likely reflect who stays in the study, not CBD becoming more potent over time. Children who don’t respond tend to stop treatment or switch medications, leaving mostly responders in the data. Randomized trials assess every patient over a fixed window regardless of response, so they give a more complete, conservative picture. The review’s authors noted that long-term results look better largely because the children still being tracked at six months or more are the ones for whom CBD is working.
Yes, but only in one prescription form. Epidiolex is the only FDA-approved CBD medication for seizures, approved for Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex. Its approval rests on randomized controlled trial data, and it doesn’t extend to over-the-counter or unregulated CBD products. Families considering CBD for pediatric epilepsy should work with a neurologist to separate FDA-sanctioned options from those that aren’t.
A review of 63 studies by Andrea D. Praticò, published in Epilepsy Research, found that about half of children with drug-resistant epilepsy (48.4%) responded to CBD, meaning their seizures dropped by at least 50%. Randomized controlled trials showed a 41.3% responder rate, compared with 49.8% in observational studies, a gap the authors link to real-world dropout patterns. Long-term studies reported a higher rate (57.4%) than short-term ones (42.8%), but the authors suggest this reflects survivor bias, since children who benefit tend to stay in studies longer, rather than CBD becoming more effective over time.
Current CBD epilepsy research focuses heavily on seizure frequency, leaving cognition and behavior largely unmeasured. The Praticò review in Epilepsy Research found that while 98.4% of the 63 included studies reported seizure outcomes, cognitive outcomes appeared in only 7.9% of studies and behavioral outcomes in just 27%.
That gap matters considerably for families managing developmental and epileptic encephalopathies like Dravet syndrome or Lennox-Gastaut syndrome, where cognitive development, behavior, and overall quality of life are just as clinically significant as seizure counts. The review’s authors specifically called for future pediatric CBD studies to incorporate standardized, longitudinal measures of cognition and behavior alongside seizure tracking — a step the field has not yet taken consistently.
The 41.3% and 41.1% figures measure different things. The 41.3% from the Epilepsy Research review is a responder rate: the share of children in CBD trial arms who had at least a 50% drop in seizures from baseline. The 41.1% from the Acta Epileptologica review is the average percent reduction in seizure frequency across a whole treatment group.
A responder rate also has limits. This measure only counts how many patients crossed a threshold. It doesn’t capture how much they improved beyond it, and it ignores placebo response, natural seizure variability, and regression to the mean. To calculate a true placebo-adjusted effect, researchers must compare treatment and placebo arms in a controlled design. Observational studies, which make up 88.9% of those in this review, can’t provide that comparison.
